Fibromyalgia Trigger Points: Mechanisms and the Efficacy of Trigger Point Therapy and Dry Needling
Introduction
Fibromyalgia (FM) is a chronic pain disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep disturbances, and cognitive symptoms. A hallmark feature historically used to diagnose FM is the presence of tender points—specific spots on the body that are painful to pressure. This article provides a deep dive into fibromyalgia trigger points and examines how trigger point therapy and dry needling can alleviate fibromyalgia pain. We will cover the nature of fibromyalgia’s pain points, the biological mechanisms underlying FM pain, evidence from human studies on trigger point-focused treatments, comparisons with other therapies, and summarized research findings in table format. All statements are supported by human research, with sources from PubMed, Cochrane, and NIH.
Overview of Fibromyalgia Trigger Points
Definition and Pain Characteristics: Fibromyalgia is a centralized pain syndrome affecting an estimated 1–5% of the population. It is defined by chronic widespread pain (pain on both sides of the body, above and below the waist) lasting at least 3 months, often accompanied by stiffness, fatigue, non-restorative sleep, and mood or memory issues. Unlike localized pain conditions, fibromyalgia’s pain is diffuse and not explained by obvious tissue damage. Patients commonly describe the pain as a constant dull ache affecting muscles across many areas.
Tender Points vs. Trigger Points: Historically, the American College of Rheumatology (ACR) defined 18 tender points (9 pairs of spots) on the body that were unusually sensitive in fibromyalgia. These tender points are found in specific locations such as the back of the head, neck and shoulder muscles (trapezius, supraspinatus), upper chest (second rib area), elbows, hips (upper outer quadrants of buttocks), and inner knees. Pressing on a tender point causes localized pain in FM patients, but notably does not typically cause referred pain (pain radiating to other areas). These tender points were used as diagnostic criteria (requiring 11 of 18 points to be painful) in older guidelines, though modern criteria focus more on generalized pain and symptom severity.
It is important to distinguish fibromyalgia’s tender points from myofascial trigger points found in myofascial pain syndrome (MPS). A myofascial trigger point (TrP) is a hyperirritable nodule within a taut band of skeletal muscle that can be felt on examination. Trigger points cause pain that can radiate in characteristic patterns (referred pain) and often result from localized muscle injury or overload. In contrast, fibromyalgia tender points are tender spots without the taut bands or localized muscle lesions and are thought to reflect a heightened generalized pain sensitivity. Key differences include:
Distribution: FM tender points are widespread and part of a generalized pain syndrome, whereas MPS trigger points are usually localized to one or a few regions (neck, back, etc.) corresponding to the affected muscle. Fibromyalgia pain is body-wide, while myofascial pain is regional.
Palpation findings: Trigger points present as a palpable taut band or knot in the muscle and pressing them often reproduces referred pain in a predictable pattern. Tender points are simply tender areas without distinct nodules or referred pain patterns.
Etiology: Myofascial trigger points often develop from muscle trauma, repetitive strain, or chronic tension, and involve a local muscle pathology. Fibromyalgia tender points have an unclear pathology – there is no evidence of ongoing tissue inflammation or damage at those sites; instead, the tenderness is likely due to central nervous system sensitization (an amplified pain perception). In other words, tender points are a symptom of a broader pain regulation problem rather than a local muscle injury.
Treatment response: Localized treatments (like injections or manual therapy) directed at true myofascial trigger points can often yield significant relief of pain and restoration of function in MPS. In fibromyalgia, however, treating tender points in isolation (for example, injecting them) tends to be much less effective because the root cause is systemic. One review noted that local treatment of fibromyalgia tender points is usually ineffective, whereas specific treatment of trigger points in MPS can be dramatically effective. This underscores that fibromyalgia pain involves more than just localized muscle knots.
Commonly Affected Areas in Fibromyalgia: Patients with fibromyalgia report the most intense tenderness in certain muscle groups. Classic tender point sites (which often overlap with common trigger point locations) include: the occipital area at the base of the skull, the neck (cervical spine) and shoulder (trapezius) muscles, the upper chest near the second rib, the lateral epicondyles of the elbows, the upper outer quadrants of the gluteal muscles, the hips (greater trochanter area), and the medial fat pad of the knees. These areas are not the only painful spots, but they are reproducibly sensitive to even mild pressure in FM patients (compared to healthy individuals who would not find such pressure painful).
Interestingly, research has shown overlap between fibromyalgia tender points and myofascial trigger points. A 2010 study found that the predefined tender point locations in fibromyalgia often coincide with common myofascial trigger points in those muscles. In other words, the spots doctors check for tenderness in fibromyalgia are frequently areas where people (even without fibro) might develop trigger points. Moreover, many fibromyalgia patients do have active myofascial trigger points in addition to widespread pain. In one study, researchers identified a total of 308 active myofascial trigger points among 30 fibromyalgia patients (about 10 trigger points per patient on average), confirmed by abnormal spontaneous electrical activity in those muscle spots. Stimulating those trigger points reproduced the spontaneous pain the fibromyalgia patients were experiencing. These findings suggest that while fibromyalgia pain is primarily a central nervous system issue, peripheral trigger points in muscles can contribute to overall pain in FM. Fibromyalgia and myofascial pain syndrome thus can co-exist, and treating peripheral pain generators (like trigger points) may help reduce the total pain load in fibromyalgia. However, fibromyalgia pain is not only due to trigger points – it is a more complex, whole-system pain sensitization condition.
Mechanisms Behind Fibromyalgia Pain
Fibromyalgia is understood as a disorder of pain regulation, involving amplified pain signaling in the nervous system (often termed central sensitization). FM patients have a heightened response to stimuli that are not painful to others, leading to hyperalgesia (exaggerated pain from painful stimuli) and allodynia (pain from normally non-painful stimuli such as light touch). Below we discuss the neurochemical and physiological mechanisms thought to underlie fibromyalgia pain, including the roles of neurotransmitters and central sensitization, and clarify how tender points fit into this mechanism.
Neurotransmitter Imbalances: Research has identified several abnormalities in pain-related neurotransmitters in fibromyalgia:
Substance P: Substance P is a neurotransmitter that facilitates pain signal transmission in the spinal cord. Fibromyalgia patients have been found to have abnormally high levels of substance P in their cerebrospinal fluid (CSF) – about three times higher than in healthy controls. This elevation is significant because excess substance P lowers pain thresholds and exaggerates pain perception. Notably, substance P levels in FM remain high chronically and do not surge further during acute pain, suggesting that the pain pathways are persistently ramped up. High substance P is considered a biological marker of FM and related chronic pain conditions, reflecting an enhanced excitatory drive in the central nervous system (spinal cord and brain).
Serotonin and Norepinephrine: Serotonin (5-HT) and norepinephrine (NE) are important neurotransmitters in the brain and spinal cord that normally help inhibit pain and regulate mood. Fibromyalgia patients show a deficit in these monoamine neurotransmitters. Clinical studies have found reduced levels of serotonin in the blood and low levels of its metabolite (5-HIAA) in the CSF of FM patients. Levels of a major NE metabolite (MPHG) in CSF are also lower in FM. This indicates an overall deficiency in serotonin and norepinephrine activity. The deficiency has functional consequences: one pain-modulating mechanism called “descending inhibitory control” (where the brain dampens pain signals in the spinal cord) is impaired in fibromyalgia. In fact, most medications that help fibromyalgia pain are those that increase serotonin and NE levels (for example, dual reuptake inhibitor antidepressants like duloxetine and milnacipran, or tricyclics like amitriptyline). The success of these drugs in reducing FM symptoms further supports the idea that low serotonin/NE contributes to fibromyalgia pain. In short, fibromyalgia involves an imbalance between excitatory facilitators of pain (high substance P, glutamate) and reduced inhibitory neurotransmitters (low serotonin and norepinephrine), tilting the system toward a state of pain amplification.
Dopamine: Dopamine is another neurotransmitter implicated in pain modulation, reward, and mood. Emerging evidence suggests dysfunction of dopaminergic pathways in fibromyalgia. One study using brain imaging found that fibromyalgia patients have a disrupted release of endogenous dopamine in response to pain in the basal ganglia (part of the brain involved in pain and mood processing). In healthy individuals, painful stimuli trigger a dopamine release (potentially as a coping or analgesic response), but in FM patients this response was blunted or uncoordinated. The dopamine dysregulation may contribute to both the pain and the mood symptoms (like anhedonia or fatigue) seen in fibromyalgia. In simpler terms, the brain’s normal dopamine-based pain suppression or reward mechanisms might not function properly in FM, potentially worsening pain perception and associated emotional distress.
Endorphins (Endogenous Opioids): Endorphins are the body’s natural painkillers, binding to opioid receptors to reduce pain. One might suspect that low endorphin levels could cause fibromyalgia pain, but research presents a nuanced picture. Some studies in the 1990s reported that FM patients had lower levels of certain endorphins (e.g., low met-enkephalin in CSF) relative to controls. This would imply an endorphin deficit contributing to pain. However, more recent evidence suggests the opioid system in FM may actually be overactive or desensitized rather than underactive. Brain imaging has shown reduced availability of mu-opioid receptors in FM patients, consistent with high levels of endogenous opioids occupying those receptors (the body may be releasing endorphins constantly in an attempt to quell pain). This could explain why fibromyalgia patients often respond poorly to opioid pain medications – their opioid receptors are already saturated or down-regulated by the body’s own endorphins. So, while fibromyalgia patients have severe pain, it’s not for lack of endorphins; rather, their nervous system is resistant to opioidergic pain relief or the endorphins are not sufficient to overcome the central sensitization. Clinically, this means opioid painkillers are usually not very effective in FM (and not recommended), whereas boosting serotonin and NE (as mentioned above) is more beneficial.
Central Sensitization and Pain Amplification: A core feature of fibromyalgia is central sensitization, which refers to an enhanced responsiveness of neurons in the central nervous system (spinal cord and brain) so that normal or minor inputs are perceived as painful. Essentially, the “volume” on pain signaling is turned up. Central sensitization can develop after an initial pain or injury triggers a prolonged increase in excitability of spinal cord neurons. In fibromyalgia, even though no ongoing tissue damage is present, the nervous system behaves as if it’s persistently under threat.
In FM patients, pain signals get amplified (“wind-up”), leading to widespread tenderness. Experimental studies show that FM patients experience an exaggerated pain response to repetitive stimulation, indicating a lowered threshold for activating pain pathways. Mechanistically, central sensitization in FM has been linked to the neurotransmitter imbalances discussed above: excess excitatory transmitters like glutamate and substance P in the spinal cord, combined with deficient inhibitory input (serotonin/NE), facilitate this state. Animal research confirms that simultaneous activation of substance P and NMDA-type glutamate receptors can induce central sensitization (a model for what happens in FM). In fibromyalgia patients, elevated glutamate levels have been detected in certain brain regions associated with pain processing (such as the insula), further supporting this excitatory-inhibitory imbalance.
The result of central sensitization is that fibromyalgia patients feel pain from stimuli that others would find innocuous. For example, a gentle finger pressure on a tender point that causes intense pain in an FM patient would only be felt as pressure (not pain) in a healthy person. This is because the FM patient’s spinal neurons are hyper-responsive (their “gain” is turned up). Additionally, pain can spread beyond its original locations. As an analogy, if a normal pain is like an isolated spark, fibromyalgia’s pain is like a fire that spreads in a dry forest – the nervous system is primed to let pain signals proliferate.
Hyperalgesia vs. Allodynia: In fibromyalgia, hyperalgesia (heightened pain from something that is normally painful) is evident by the lowered pressure pain thresholds – FM patients flinch at pressures that wouldn’t bother others. Allodynia (pain from non-painful stimuli) can also occur; for instance, a light touch or massage might feel painful. These phenomena are direct consequences of central sensitization. Pain is essentially “over-amplified” in the spinal cord and brain. Notably, central sensitization can also lead to pain spreading to areas that were not originally injured or painful. This helps explain why fibromyalgia pain is so widespread and not confined to one region.
Tender Points and Central Sensitization: Fibromyalgia’s tender points are thought to be an outcome of this central pain state. There is no evidence of inflammation or tissue pathology at tender points on biopsy or imaging; instead, these points are likely regions where even normal muscle strains or daily activities produce pain due to the lowered pain threshold. In essence, fibromyalgia tender points are a reflection of a hyper-sensitized central nervous system, rather than being the root cause of pain. This contrasts with myofascial trigger points, which are localized sources of pain (peripheral generators) that can trigger central sensitization if numerous or severe. In FM, central sensitization exists from the start, possibly due to genetics and environmental triggers, without a need for ongoing nociceptive input – though, as noted earlier, many FM patients also have some trigger points or other pain sources that may further drive the central sensitization.
In summary, fibromyalgia pain arises from a combination of neurotransmitter abnormalities (high substance P and glutamate, low serotonin and norepinephrine, dopamine dysregulation) and the phenomenon of central sensitization, which together cause a state of generalized pain amplification (hyperalgesia). Tender points are a diagnostic artifact of this state – they indicate spots where the hyperalgesia is easily elicited – whereas myofascial trigger points are specific muscle knots that can occur in anyone, but may be more common or problematic in FM due to the lack of effective pain inhibition. Understanding these mechanisms provides a rationale for treatments: for example, medications that adjust neurotransmitters, or therapies that reduce peripheral pain input (like trigger point therapy) to ease the burden on an overwhelmed nervous system. The next sections will explore how targeting trigger points – the localized muscle knots – through manual therapy or dry needling can modulate fibromyalgia pain, and how these approaches compare to other treatments.
Trigger Point Therapy and Dry Needling for Fibromyalgia
Fibromyalgia is fundamentally a central pain disorder, but given that many patients have coexisting muscle trigger points, therapies directed at these trigger points can be helpful. Trigger point therapy generally refers to techniques that deactivate or relieve myofascial trigger points – this can include manual pressure/massage, trigger point injections, or dry needling. Dry needling (DN) is a specific method where thin needles (without medication) are inserted directly into trigger points. It is similar to acupuncture in technique, but whereas traditional acupuncture follows meridian points, trigger point dry needling targets taut bands of muscle to provoke a release of the contraction knot. For fibromyalgia patients, trigger point therapies aim to reduce localized neuromuscular abnormalities and thereby decrease peripheral sources of pain, which in turn can calm down the central nervous system’s sensitization.
Mechanisms of Pain Relief from Trigger Point Therapies
Local Neuromuscular Effects: An active myofascial trigger point is characterized by excessive acetylcholine release at the neuromuscular junction, leading to a sustained muscle fiber contraction (a taut band) and local ischemia (reduced blood flow) with a buildup of pain chemicals. Dry needling a trigger point often elicits a distinct local twitch response – an involuntary quick contraction of the muscle fibers. This twitch is a good sign: it indicates the needle hit the dysfunctional motor end-plate region. The twitch likely helps “reset” the muscle fibers and normalize neuromuscular function. Research suggests that the local twitch response can interrupt the electrical activity (“end-plate noise”) of the trigger point, which correlates with an immediate reduction in pain and tightness. Essentially, needling forces the contracted fibers to momentarily contract and then relax. After a twitch, the trigger point’s taut band often softens, circulation improves, and the muscle’s stretchability increases.
Dry needling and other trigger point therapies also cause micro-trauma to the tissue which triggers a healing response. The needle or pressure causes a small injury that the body responds to with improved blood flow and release of growth factors, helping the muscle tissue remodel. Moreover, stretching or pressuring the trigger point can disrupt actin-myosin bonds in the tight muscle sarcomeres, physically relaxing the contraction. In manual trigger point release therapy, a therapist might press firmly on the knot (ischemic compression) until it “releases,” which similarly restores normal muscle length and resting tension.
Reduction of Inflammation and Nociceptive Chemicals: Active trigger points are known to harbor an inflammatory milieu. Microdialysis studies of trigger points have found elevated levels of pro-inflammatory and pain-signaling substances such as substance P, calcitonin gene-related peptide (CGRP), bradykinin, interleukins, and tumor necrosis factor-alpha (TNFα) in the immediate vicinity of the TrP, compared to normal muscle tissue. These chemicals activate local pain receptors and contribute to peripheral sensitization. By mechanically stimulating the trigger point (with a needle or pressure), we can cause a washout or release of these accumulated chemicals. In fact, after effective dry needling or trigger point injection, studies have observed decreased concentrations of pain mediators and normalization of pH in the tissue. Thus, trigger point therapy can reduce the local source of nociceptive (pain) input by flushing out or dispersing the irritating substances and improving blood flow to the area. Less irritating chemical stimulation means less pain signaling sent to the spinal cord from that spot.
Additionally, needling a trigger point often results in an immediate increase in pressure pain threshold at that spot – it hurts less to press on it – reflecting the reduction in peripheral sensitization. Overall, calming down the trigger point’s abnormal chemistry and activity reduces ongoing nociceptor firing that would otherwise barrage the central nervous system.
Central Modulation and Pain Perception: Interestingly, treatments like dry needling don’t only work peripherally; they also produce central nervous system effects. The act of needling and the subsequent afferent nerve signals can trigger reflex responses in the spinal cord and brainstem that modulate pain. Functional MRI studies suggest that dry needling can activate descending pain inhibitory pathways, including areas like the periaqueductal gray (PAG) in the midbrain which is a key center for endogenous pain suppression. By activating these higher centers, dry needling may prompt the release of neurotransmitters such as endorphins, serotonin, norepinephrine, or even hormones like oxytocin that have analgesic properties. One hypothesis is that dry needling of a painful point could stimulate a brief surge of oxytocin in the central nervous system, contributing to pain relief and relaxation, though more research is needed in this area.
Crucially for fibromyalgia, reducing peripheral pain signals can help “dial down” central sensitization. Recall that central sensitization in FM may be partly maintained by continuous incoming pain signals from muscles, joints, etc. Trigger points can be significant pain generators. When trigger point therapy quiets these hotspots, the overall nociceptive input to the spinal cord drops, which may allow an overactive central nervous system to settle. As one review described, myofascial trigger points can become sources of ongoing nociceptive input that reinforce central sensitization, so eliminating those sources can break the cycle. Dry needling has been shown to reduce the excitability of central pain neurons by alleviating the peripheral drive from trigger points. In essence, it’s like turning off some of the “noise” going into an already sensitive amplifier (the spinal cord), so the system isn’t as overwhelmed. This can translate into widespread pain relief beyond just the local area treated.
Summary of Mechanisms: Trigger point therapies like dry needling work through a combination of local and central effects. Locally, they normalize muscle fiber activity (resolving taut bands), improve blood flow, and decrease the concentration of pain-inducing chemicals in the muscle tissue. They often provoke a beneficial twitch response that interrupts the trigger point circuit. Systemically, they send signals that engage the body’s own pain modulatory systems and reduce the overall incoming pain traffic to the CNS. The net effect is pain relief, improved range of motion, and reduced muscle tension in the areas treated, which for fibromyalgia patients can mean less localized pain and potentially an easing of their general pain sensitivity.
Evidence from Human Studies: Trigger Point Therapy & Dry Needling in Fibromyalgia
A growing number of clinical studies have evaluated dry needling and other trigger point therapies in fibromyalgia patients. Overall, evidence from randomized controlled trials (RCTs) suggests that these interventions can yield significant short-term improvements in pain and other symptoms. Below is a summary of key findings from human studies (more detailed data are presented in Table 1):
Dry Needling vs. Standard Care: Casanueva et al. (2014) conducted an RCT with 110 fibromyalgia patients who were severely affected by pain. The treatment group received dry needling on fibromyalgia tender points once weekly for 6 weeks in addition to their usual medical management, while the control group received medical management alone. The results were notably positive – after 6 weeks, the dry needling group had significantly lower pain intensity (measured by visual analog scale, VAS), less fatigue, and improved quality of life compared to controls. Pressure pain thresholds (the amount of pressure required to cause pain) increased in the treated patients, indicating reduced tenderness. Impressively, these improvements persisted when re-evaluated 6 weeks after the therapy ended. The authors concluded that even a short course of weekly dry needling can produce meaningful short-term relief for fibromyalgia patients.
Dry Needling vs. “Sham” or Alternative Therapy: To test if the benefits are truly due to needle action and not just placebo, Castro-Sánchez et al. (2017) compared dry needling of trigger points in spinal muscles to a sham technique (they used application of cross-tape over trigger point areas as a placebo-like control) in 64 FM patients. After 5 weeks of treatment, the dry needling group showed greater reduction in trigger point sensitivity (as evidenced by higher pressure pain thresholds in several muscles) than the cross-tape group. Both groups had some improvement in spinal mobility, and the mobility gains were similar, suggesting a modest placebo effect or general therapeutic effect of touch. However, the clear differences in pain pressure thresholds indicate that dry needling specifically decreased the hyperalgesia of myofascial trigger points better than the control
. This supports the specific efficacy of the needle intervention for pain relief in FM.
Dry Needling vs. Manual Trigger Point Release: An RCT by Castro-Sánchez et al. (2019) compared dry needling to manual myofascial release therapy (a hands-on physical therapy technique to release trigger points) in fibromyalgia patients. Both treatments targeted trigger points in the neck/shoulder region (common pain spots in FM). After 4 weeks, dry needling produced greater improvements than manual therapy in multiple outcomes. Specifically, the dry needling group had a larger increase in pressure pain thresholds of neck trigger points (meaning those points became less painful) and significantly better improvements in domains of quality of life (physical functioning, vitality, bodily pain scores, etc.). They also reported greater reductions in fatigue, anxiety, and depression scores compared to the myofascial release group. Both treatments did help (and both reduced overall pain and the impact of fibromyalgia to some extent), but dry needling had an edge in efficacy. The implication is that while manual trigger point therapy is beneficial, the needle may achieve a deeper or more complete deactivation of trigger points, yielding superior outcomes in fibromyalgia. The authors noted that dry needling led to significant short-term relief of myofascial trigger point pain and associated symptoms (sleep quality, mood) in these patients.
Dry Needling vs. TENS (Electrical Therapy): In Castro-Sánchez et al. (2020), an RCT with 74 fibromyalgia patients, dry needling was compared to transcutaneous electrical nerve stimulation (TENS), another non-pharmacological pain treatment. After 6 weeks of treatment, both groups experienced pain reductions, but the dry needling group had greater improvements across all dimensions of pain (sensory and affective pain scores, overall pain severity on the McGill questionnaire, and VAS ratings). Dry needling also showed more favorable effects on certain objective measures like heart rate variability and galvanic skin response, which are related to autonomic nervous system function. This suggests dry needling might not only reduce pain but also modulate the autonomic imbalances often seen in FM. Both dry needling and TENS are thought to activate pain-inhibitory pathways (TENS via electrical stimulation of nerves), but in this study dry needling provided superior pain relief.
Trigger Point Injections: While dry needling uses no injectate, some fibromyalgia patients receive trigger point injections with anesthetics (like lidocaine) or other agents. Rigorous studies are fewer in FM specifically. However, a notable trial by Hong (1996) compared outcomes of trigger point lidocaine injections in patients with myofascial pain alone versus those with myofascial pain plus fibromyalgia. Both groups eventually benefited (at 2 weeks post-injection both had significant pain reduction and increased range of motion), but the fibromyalgia patients had a slower and smaller immediate response to the injections. Right after injection, FM patients improved only in range of motion, whereas non-FM patients had immediate pain relief and threshold increases. Moreover, FM patients experienced more post-injection soreness. This suggests that fibromyalgia’s central sensitization dampens the response to even potent local treatments – they still help, but not as dramatically or quickly. The conclusion was that trigger point injections are beneficial for FM patients, but their effect is attenuated and delayed compared to typical myofascial pain syndrome patients. This finding aligns with the idea that FM pain is multifactorial; removing one trigger point’s input helps, but widespread pain may remain until many or most triggers are treated and the central state calms.
Overall, human studies indicate that trigger point therapies can be an effective component of fibromyalgia treatment, providing relief in pain intensity and improving functional measures. Dry needling, in particular, has gathered evidence for short-term efficacy in improving pain, pressure pain thresholds (i.e. reducing tenderness), fatigue, stiffness, and even psychological well-being in fibromyalgia. A 2022 systematic review of 25 studies (including 4 dry needling RCTs in FM and 21 acupuncture RCTs) concluded that both dry needling and acupuncture significantly improve fibromyalgia symptoms in the short term, including reductions in pain, fatigue, sleep disturbances, and improved quality of life. Importantly, these techniques were reported as safe and had acceptable tolerability in the studies, with mild muscle soreness being the most common side effect.
One limitation to note is that most studies demonstrate short to medium-term benefits (weeks to a few months). Long-term efficacy (maintaining relief over many months or years) is less established, often requiring periodic treatment sessions to sustain the improvements. This is not surprising, as fibromyalgia is chronic and likely needs ongoing management. Nonetheless, adding trigger point therapy or dry needling to a fibromyalgia patient’s regimen can yield meaningful improvements, especially for those who have prominent muscular pain components.
The following table (Table 1) summarizes key clinical studies of dry needling and trigger point therapies in fibromyalgia:
Table 1: Human Studies of Dry Needling/Trigger Point Therapy in Fibromyalgia
| Study (Year) | Design & Sample | Intervention (vs. Control) | Outcomes | Key Findings |
|---|---|---|---|---|
| Casanueva et al., 2014 pmc.ncbi.nlm.nih.gov | RCT, n=110 FM patients (severe symptoms) | Dry needling of 9 tender points weekly for 6 weeks + standard medical care vs. standard care alone | Pain (VAS), Fatigue (VAS), Pressure Pain Threshold (PPT), SF-36 QOL scores, etc. | Dry needling group improved significantly: end of treatment and 6-week follow-up showed lower pain and fatigue scores, higher PPT (less tenderness), and better SF-36 quality of life than controls pmc.ncbi.nlm.nih.gov. Short-term DN yielded notable relief in widespread pain and fatigue. |
| Castro-Sánchez et al., 2017 pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov | Single-blind RCT, n=64 FM patients (ages 27–58) | Dry needling of spinal muscle TrPs (thoracic & lumbar) 4×/week for 5 weeks vs. cross-tape applied on TrP locations (sham) | Spinal mobility, Trigger point pressure pain thresholds | Dry needling reduced TrP sensitivity more than sham: DN group had higher PPTs (less pain) in muscles like latissimus dorsi, multifidus, quadratus lumborum pmc.ncbi.nlm.nih.gov. Spinal mobility improved similarly in both groups, but DN specifically decreased myofascial pain in the back pmc.ncbi.nlm.nih.gov. |
| Castro-Sánchez et al., 2019 pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov | RCT, n=64 FM patients (27–58 y/o) | Dry needling of cervical (neck) muscle TrPs 2×/week for 4 weeks vs. manual myofascial release therapy on the same areas | Neck TrP PPT, Fibromyalgia Impact Questionnaire (FIQ), SF-36 QOL, sleep quality, anxiety/depression, fatigue | Both groups improved, but dry needling was superior: DN group had greater increases in neck PPTs (pain threshold), and significantly better improvements in multiple SF-36 domains (pain, physical role, vitality, mental health) pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov. DN also led to larger reductions in FM symptom impact, anxiety, depression, and fatigue pmc.ncbi.nlm.nih.gov. DN outperformed manual therapy in relieving pain and enhancing quality of life short-term. |
| Castro-Sánchez et al., 2020 pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov | RCT, n=74 FM patients | Dry needling 1×/week for 6 weeks (multiple TrPs) vs. TENS (electrical nerve stimulation) 20 min sessions 1×/week for 6 weeks | Pain (McGill questionnaire scores, VAS), Autonomic measures (heart rate variability, galvanic skin response), oxygen saturation | Dry needling yielded greater pain reduction than TENS: DN group showed significantly lower pain ratings across sensory, affective, and overall pain dimensions (p=0.001) pmc.ncbi.nlm.nih.gov. DN also produced favorable changes in heart rate variability indicators of autonomic balance pmc.ncbi.nlm.nih.gov. Both treatments reduced pain, but DN was more effective in relieving fibromyalgia pain and modulating certain physiological markers pmc.ncbi.nlm.nih.gov. |
| Hong et al., 1996 pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov | Blinded trial, n=18 (Fibro + MPS: n=9, MPS-only: n=9) | Trigger point injection (0.5% lidocaine) into trapezius TrP (both groups) – comparison of response between FM vs. non-FM patients | Pain intensity (PI), PPT, Range of motion, assessed pre-injection, immediately post-injection, and 2 weeks post | Both groups benefited by 2 weeks, but FM patients had a blunted immediate response: immediately after injection, FM group improved only in ROM while MPS-only group had significant pain relief and PPT increase pubmed.ncbi.nlm.nih.gov. Two weeks later, FM patients did catch up with significant pain improvement. FM group also had more intense and longer-lasting post-injection soreness pubmed.ncbi.nlm.nih.gov. Conclusion: TrP injections help FM patients, but with delayed and smaller effect vs. typical MPS patients pubmed.ncbi.nlm.nih.gov. |
(Abbreviations: RCT = randomized controlled trial; FM = fibromyalgia; MPS = myofascial pain syndrome; TrP = trigger point; PPT = pressure pain threshold; VAS = visual analog scale; QOL = quality of life; TENS = transcutaneous electrical nerve stimulation.)
As shown in Table 1, multiple high-quality studies have demonstrated that treating myofascial trigger points (via dry needling or other means) can lead to statistically and clinically significant improvements in fibromyalgia symptoms. The benefits include reduced localized pain (higher pain pressure thresholds), improvements in global pain ratings, less fatigue, better sleep, and enhanced overall well-being in the short term. Dry needling in particular emerges as a valuable tool, often outperforming sham or even other physical therapies in head-to-head trials.
It’s important to emphasize that trigger point therapy and dry needling are typically used as adjuncts in fibromyalgia treatment, rather than standalone cures. Fibromyalgia’s complexity means patients usually require a multi-modal approach (medications, exercise, stress management, etc., discussed next). However, for a patient whose fibromyalgia includes significant myofascial pain components, adding trigger point-focused treatment can provide relief of “hotspots” of pain, which may make it easier for them to engage in other therapies like exercise. Also, relieving muscle pain can improve sleep and day-to-day function, which has ripple effects on fatigue and mood.
Regarding safety: Dry needling is generally safe when performed by trained professionals. Common side effects are temporary soreness, slight bleeding or bruising at the needling site, and occasionally vasovagal reactions (feeling lightheaded). Serious complications (e.g., pneumothorax from needling near the lungs) are rare but underscore the need for proper technique and anatomic knowledge by the practitioner. Trigger point injections carry a small risk of infection or bleeding, but when done with sterile technique these risks are minimal. Fibromyalgia patients might experience more post-treatment soreness (as Hong’s study noted), likely due to their heightened pain sensitivity, so providers often use gentler techniques or fewer needles initially and encourage self-care (heat, stretching) after sessions.
In summary, trigger point therapy and dry needling provide pain relief in fibromyalgia by deactivating painful muscle nodules and thereby reducing both peripheral and central drivers of pain. Human trials support their efficacy in improving pain, functional outcomes, and quality of life in the short term. These treatments integrate well with other fibromyalgia therapies, which we will compare in the next section.
Comparison with Other Fibromyalgia Treatments
Fibromyalgia being a complex syndrome, a wide array of treatments are used – ranging from pharmacological options to various non-drug therapies and lifestyle modifications. Here, we compare trigger point therapy and dry needling with other common treatment modalities, examining their effectiveness, advantages, and limitations. A comprehensive management plan for fibromyalgia often involves combining multiple approaches, tailored to the individual. In fact, current guidelines and experts endorse a multidisciplinary approach: patient education, exercise, cognitive behavioral therapy, and possibly medications, rather than relying on any single treatment.
Below is an overview of how trigger point-focused treatments stack up against other therapies:
Medications: There are three FDA-approved medications for fibromyalgia: duloxetine and milnacipran (both SNRIs that increase serotonin and norepinephrine) and pregabalin (an anticonvulsant that reduces neuronal excitability). These and other off-label meds (e.g., amitriptyline, cyclobenzaprine, gabapentin, tramadol) can reduce pain and improve sleep or mood in some patients. However, their efficacy is moderate at best – only a subset of patients get substantial relief, and many experience side effects like drowsiness, weight gain, or dry mouth. Clinical trials show these drugs typically achieve a ~30% pain reduction in about 30–50% of patients, which is meaningful but not a cure. The advantage of medications is they treat the widespread nature of fibromyalgia (systemic action for systemic pain) and can also address comorbid issues (e.g., antidepressants help depression/anxiety, pregabalin may improve sleep). The limitation is that no medication fully eliminates fibromyalgia pain, and long-term use can be hampered by side effects. By comparison, trigger point therapy/dry needling targets specific pain generators and has no systemic side effects. For a patient with prominent muscle knot pain, dry needling might produce more immediate relief in that area than any pill could. On the other hand, medications can help diffuse symptoms like overall fatigue or diffuse pain which local therapy won’t address. Often, patients will use both – e.g., an SNRI for general pain control and sleep, plus periodic dry needling for focal muscle flares. It’s worth noting that because fibromyalgia patients often have augmented opioid activity and poor response to opioids, guidelines discourage opioid analgesics. Instead, non-opioid options and non-drug therapies (like dry needling) are preferred to avoid risks of dependency and side effects.
Acupuncture: Acupuncture is an ancient Chinese medicine technique superficially similar to dry needling (both use fine needles). The difference is that acupuncture usually follows meridian points and traditional energy concepts, whereas dry needling directly targets myofascial trigger points. In practice, there can be overlap (many acupuncture points correspond to common trigger points). Acupuncture has been researched in fibromyalgia extensively. Systematic reviews and meta-analyses (including the one cited earlier) conclude that acupuncture can produce significant short-term improvements in pain, sleep quality, and fatigue in fibromyalgia, superior to no treatment or standard care. In trials comparing acupuncture to sham (placebo) acupuncture, results are mixed but tend to show real acupuncture has modest specific benefits beyond placebo. Both acupuncture and dry needling have cumulative effects – typically delivered in a series of sessions. The advantage of acupuncture is that it is a holistic approach, potentially addressing not just pain but also energy, stress, and well-being; many patients find it relaxing. It is generally safe with minimal side effects. Dry needling could be seen as a more focused, Western medical variant primarily for musculoskeletal pain. In fibromyalgia, acupuncture and dry needling appear roughly comparable in effectiveness, as noted by the absence of direct comparison trials but similar outcomes in separate studies. Neither involves drugs, which is an advantage for patients looking to minimize medication use. One limitation is that benefits may wane after treatment stops; ongoing sessions might be needed for sustained relief. Also, access to skilled practitioners (acupuncturists or physical therapists trained in dry needling) can be a barrier for some.
Physical Therapy and Exercise: Exercise is one of the most universally recommended therapies for fibromyalgia. Aerobic exercise (e.g., brisk walking, swimming, cycling) and strength training have strong evidence for improving pain threshold, physical function, and overall wellness in FM. A Cochrane review found that supervised aerobic exercise training leads to significant improvements in fibromyalgia symptoms and fitness, with “gold” level evidence for efficacy. Regular exercise can counteract the deconditioning that often accompanies FM and can raise endorphin levels, improve sleep, and reduce fatigue. The advantage of exercise is its broad benefits (physical and mental health, no cost once learned), but the challenge is getting started and adherence – fibromyalgia patients, due to pain and fatigue, often struggle to begin exercise programs. This is where therapies like trigger point release can help: by reducing focal pain, patients might tolerate activity better. Physical therapy (PT) can include gentle stretching, hydrotherapy, posture correction, and techniques like myofascial release massage. These can alleviate stiffness and pain and improve range of motion. Compared to dry needling, manual PT techniques are very safe and non-invasive, but they may require frequent sessions and the results might be more short-lived if not coupled with self-exercise. Dry needling can be considered a specialized adjunct within the PT domain. Ultimately, exercise + some form of manual or needling therapy often go hand-in-hand – PTs might use dry needling to calm trigger points and then prescribe exercises to maintain the improvement. Exercise addresses the central aspect of FM by improving pain modulation (exercise can enhance serotonin, growth hormone, etc.), whereas trigger point therapy addresses the peripheral pain sources. Both are complementary. Limitations of exercise are initial symptom exacerbation (it must start low and go slow to avoid flares) and the need for motivation and consistency. Trigger point therapy’s limitation is that it doesn’t improve cardiovascular fitness or strength – it’s purely for pain relief – so it should not replace exercise, but facilitate it.
Cognitive Behavioral Therapy (CBT) and Psychological Therapies: Fibromyalgia has significant psychosocial dimensions – stress can worsen symptoms, and the chronic pain leads to anxiety, depression, and maladaptive thought patterns in some cases. CBT is a form of therapy that helps patients reframe negative thoughts, develop coping strategies, and gradually increase activities in a paced way. According to evidence-based guidelines, CBT is considered a first-line or recommended therapy for fibromyalgia. It has been shown to provide small-to-moderate improvements in pain, mood, and function. For instance, a Cochrane review of 23 studies found CBT leads to modest pain reduction and improved mood immediately after treatment, with some sustained benefit at 6+ months. The advantage of CBT is that it equips patients with long-term self-management skills and addresses the mental/emotional toll of fibromyalgia, something physical treatments alone cannot do. It also has no physical side effects. The limitation is that it requires a time commitment (weekly sessions over weeks to months) and active mental work from patients, and its effects on pain, while real, are typically less direct or immediate than a medical or physical intervention. For example, one won’t walk out of a CBT session with lower pain that day – but over time, one might report lower average pain and less distress. Trigger point therapy, conversely, can reduce pain the same day but doesn’t teach self-management. The best outcomes often occur when psychological therapy is combined with physical treatments – addressing both mind and body. Some patients who are needle-averse or not responding to PT might prefer focusing on mind-body techniques (like mindfulness, meditation, or CBT) to manage pain perception.
Lifestyle and Integrative Approaches: Many lifestyle modifications can help fibromyalgia. Sleep improvement is critical – following good sleep hygiene, treating insomnia (possibly with medications or supplements), since non-restorative sleep exacerbates pain. Stress reduction through meditation, yoga, tai chi, or other relaxation techniques has shown benefit and is often recommended. In fact, practices like tai chi and yoga have evidence of improving fibromyalgia symptoms and are sometimes as effective as aerobic exercise for some patients. Dietary changes (like anti-inflammatory diets or avoiding certain foods) are anecdotal but some patients find triggers (like gluten or excess sugar) might worsen symptoms. Supplements like vitamin D (if deficient) or magnesium may be tried, though evidence is limited. The advantage of lifestyle interventions is that they empower patients to control some aspects of their condition and generally improve overall health. They often have overlap with other treatments: for instance, yoga provides gentle exercise, stress reduction, and stretches muscle areas (thus could indirectly help what trigger point therapy does). The limitation is that these approaches require consistent effort and their effects can be subtle or gradual. For example, practicing meditation daily may over time lower one’s pain reactivity, but it requires discipline. They are best used in conjunction with medical and physical therapies.
In comparing trigger point therapy/dry needling with these other treatments, a few points stand out:
Scope of Effect: Trigger point treatments have a localized effect (with some secondary systemic relief), whereas medications and CBT address the global condition. Thus, they are not mutually exclusive but complementary. Dry needling won’t treat fibrofog (cognitive issues) or fatigue, but improving local pain can help a person become more active, which then improves fatigue. Medications might reduce overall pain by a notch but still leave specific muscle knots painful – those could be fixed with needling.
Speed of Relief: Dry needling and trigger point injections can produce immediate pain relief in the areas treated (minutes to days). Medications usually take weeks to dose optimize and work, CBT takes weeks, exercise takes several weeks to months for full benefit. Thus, trigger point therapy can provide a “quick win” in pain reduction. However, its longevity is variable – some patients have pain relief for months from one session, others for days. Continuing a maintenance schedule (e.g., monthly sessions) might be needed. Medications and lifestyle changes are more about continuous management.
Side Effect Profiles: Trigger point therapy (dry needling/massage) side effects are mostly soreness or transient pain increase, but no systemic effects. In contrast, medications can have systemic side effects (some quite bothersome like weight gain or cognitive dulling). CBT and exercise side effects are minimal (exercise can cause soreness too, and risk of injury if done improperly). For patients who cannot tolerate medications, non-drug treatments like dry needling, exercise, and CBT become the mainstay.
Patient Preference: Some patients prefer not to take medications long-term and find hands-on therapies more acceptable. Others might dislike needles or find massage too painful during flares, so they lean more on medication or gentle exercise. It’s very individual. Fibromyalgia treatment is often trial-and-error; what works best is highly personal. For instance, one patient may swear by acupuncture and yoga, another finds relief with pregabalin and trigger point injections, another needs a combination of five different things including therapy and swimming. Combining modalities tends to yield the best results, addressing different aspects of the syndrome.
To illustrate the relative effectiveness of these modalities, Table 2 provides a comparative summary:
Table 2: Comparison of Fibromyalgia Treatment Modalities
| Treatment Approach | Mechanism/Target | Benefits | Limitations |
|---|---|---|---|
| Trigger Point Therapy (manual pressure, massage, trigger point injections) | Releases myofascial trigger points (peripheral pain generators); reduces localized muscle tension and nociceptive input. | • Effective relief of localized muscle pain and knots pubmed.ncbi.nlm.nih.gov. • Can improve range of motion and referred pain patterns. • Quick onset of pain relief in treated areas (often same day). • Injections (with lidocaine) can give more prolonged relief per point. | • Treats only the trigger point – doesn’t directly address widespread pain or central sensitization. • Relief may be temporary; trigger points can recur, requiring repeated sessions. pubmed.ncbi.nlm.nih.gov • Injections involve needles/medication (slight risk of infection, soreness). • Manual pressure can be painful during treatment for sensitive patients. |
| Dry Needling (intramuscular) | Inserts thin needles into trigger points to provoke a twitch and deactivate the point; reduces peripheral and central sensitization pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov. | • Improves localized and even generalized pain (by removing pain sources) pmc.ncbi.nlm.nih.gov. • Increases pressure pain thresholds (i.e., reduces tenderness) in treated regions pmc.ncbi.nlm.nih.gov. • Can improve associated symptoms (fatigue, sleep, anxiety) when pain is relieved pmc.ncbi.nlm.nih.gov. • No systemic drugs involved (low side effect profile). | • Requires trained provider; involves needles which some may fear. • Mild post-needling soreness is common, especially in FM pubmed.ncbi.nlm.nih.gov. • Typically requires multiple sessions for sustained benefit. • Primarily addresses musculoskeletal aspects of FM, not other symptoms (e.g., cognitive issues). |
| Medications (e.g., duloxetine, milnacipran, pregabalin, amitriptyline) | Various: SNRIs boost serotonin/NE, anticonvulsants calm neural overactivity, TCAs for sleep, analgesics for pain. Aim to rebalance neurotransmitters and dampen central pain processing. | • Systemic relief: can reduce widespread pain and improve sleep/fatigue (duloxetine, amitriptyline) pmc.ncbi.nlm.nih.gov. • Addresses mood or anxiety comorbidities (antidepressants). • Convenient (oral meds) for long-term management; don’t require office visits. | • Moderate efficacy: only a subset achieve major improvement; many get partial relief. pmc.ncbi.nlm.nih.gov • Side effects are common (e.g., nausea, drowsiness, dizziness, weight gain). • Some patients are medication-intolerant or prefer to avoid drugs. • Opioids generally ineffective and not recommended in FM pmc.ncbi.nlm.nih.gov. |
| Acupuncture | Stimulates specific points (often overlaps with TrPs) to modulate “Qi” and neurologic signaling; can trigger endorphin release and alter pain pathways. | • Short-term improvements in pain and stiffness in FM, comparable to dry needling pmc.ncbi.nlm.nih.gov. • Holistic effects: can also alleviate stress and improve well-being. • Low risk procedure; sessions can be relaxing. | • Requires ongoing sessions for sustained effect (pain tends to return over weeks-months if not maintained). • Results can vary; some patients are “responders” more than others (genetic factors?). • Access to qualified acupuncturists and possible cost issues if not covered by insurance. |
| Exercise (Physical Therapy) | Aerobic exercise increases endorphins and conditioning; strength training builds muscle resilience; stretching improves flexibility. Mitigates central pain amplification via improved pain inhibition and reduced inflammation. | • Strong evidence for benefit: improves overall function, reduces pain severity, and boosts mood pubmed.ncbi.nlm.nih.gov. • Addresses deconditioning and fatigue over time; increases energy levels. • Empowers patient’s self-management; health benefits beyond fibromyalgia (heart, weight, etc.). | • Initial barrier: patients in pain may struggle to start exercising; requires gradual progression and perseverance. • Overexertion can cause flares – need supervised or educated approach to avoid “boom-bust” cycle. • Improvements are gradual (weeks); not an immediate pain fix like injections might be. |
| Cognitive Behavioral Therapy (and other psychological therapies) | Reshapes negative thought patterns, teaches coping strategies, pain distraction, and pacing techniques; aims to reduce pain amplification from stress and improve mental health. | • Improves coping and reduces perceived pain modestly pmc.ncbi.nlm.nih.gov. • Reduces depression, anxiety, and improves sleep and fatigue by addressing insomnia or stress behaviors pmc.ncbi.nlm.nih.gov. • Long-term skills – benefits can persist if strategies are continued, even after therapy ends. | • Requires significant time commitment (weekly therapy over months). • Pain reduction is real but typically small (adjunctive role) pmc.ncbi.nlm.nih.gov. • Access and cost can be issues; not all patients open to psychological therapy due to stigma or preferences. • Does not directly change physical aspects of FM (but can indirectly help by improving adherence to exercise, etc.). |
| Lifestyle & Integrative (sleep hygiene, stress reduction, yoga, tai chi, diet) | Targets triggers and contributors: improves restorative sleep; activates relaxation response; gentle mind-body exercise (yoga/tai chi) combines physical activity with stress relief; anti-inflammatory diet may reduce systemic inflammation. | • Holistic improvement: better sleep and stress management often reduce pain intensity and frequency of flares. • Mind-body exercises (yoga, tai chi) have shown efficacy similar to aerobic exercise in FM trials, improving pain and function with low impact on joints. • Patients gain sense of control and often side benefits (e.g., weight loss, improved mood, metabolic health). | • Changes can be challenging to implement (e.g., maintaining sleep schedule, regular meditation routine). • Evidence for diet is not as robust – individual results vary; some diets might help subsets of patients but not universally proven. • Usually need to be combined with medical/physical treatments; alone they may be insufficient for severe symptoms. • Progress is gradual; these are supportive therapies and require continuous practice. |
As Table 2 outlines, each modality has its niche. Trigger point therapy and dry needling excel at addressing the musculoskeletal pain component of fibromyalgia, offering relatively rapid relief for muscle-related pain and a low side-effect burden. They fill a gap that systemic medications don’t directly target (i.e., the knotted muscle spasms). However, they do not tackle the entire syndrome (e.g., they won’t improve cognitive “fibro fog” or general fatigue).
In contrast, medications and exercise target the global mechanisms (neurotransmitters and deconditioning, respectively) and can reduce widespread pain and improve energy – but they might not fully relieve specific tender spots. CBT and stress management improve patients’ resilience and coping, indirectly lowering the impact of pain on their life, though they don’t remove the pain stimuli. Acupuncture sits somewhat between dry needling and other modalities, sharing mechanism similarities with dry needling but framed in a holistic practice.
In practice, an integrative approach is often best. For example, a patient might use an SNRI medication to raise pain-inhibiting neurotransmitters, attend physical therapy for an exercise program and dry needling to treat trigger points, practice yoga or tai chi for gentle exercise and relaxation, and utilize CBT techniques to manage stress and improve sleep. This combination has a synergistic effect – addressing central pain processing, peripheral pain sources, physical conditioning, and psychological well-being together. Indeed, multidisciplinary fibromyalgia programs that incorporate education, aerobic exercise, cognitive therapy, and medications as needed have shown greater improvements than any single modality alone.
It’s also worth mentioning patient education: simply understanding fibromyalgia can help reduce fear and catastrophizing, which in turn can reduce pain intensity. Educating patients that their pain, while real, does not indicate damage and can be managed, often improves outcomes. Trigger point therapy sessions can serve as opportunities for patient education about muscle health, posture, ergonomics, and self-stretching, empowering patients to prevent some pain recurrence.
In conclusion, trigger point therapy and dry needling are valuable components of fibromyalgia management, especially for patients with prominent muscular pain. They compare favorably with many standard treatments in terms of improving pain and function, and have particular advantages like immediacy of effect and low systemic burden. However, they should be seen as part of a comprehensive treatment strategy. When combined with aerobic exercise, appropriate medications, psychological support, and lifestyle adjustments, trigger point-focused therapies help address fibromyalgia from multiple angles – ultimately improving the patient’s quality of life more than any single therapy could.
Conclusion
Fibromyalgia is a multifaceted chronic pain syndrome, and its management requires a nuanced, individualized approach. Fibromyalgia trigger points (tender points) are a hallmark of the condition, representing areas of exaggerated pain sensitivity due to central sensitization. These differ from classical myofascial trigger points, which are localized muscle knots causing referred pain. Nonetheless, many fibromyalgia patients also develop myofascial trigger points, which can further amplify their pain.
Understanding the mechanisms behind fibromyalgia – including neurotransmitter imbalances (high substance P and glutamate, low serotonin, norepinephrine, and dopamine dysregulation) and the phenomenon of central sensitization – provides a rationale for targeted therapies. It becomes clear that while fibromyalgia is maintained by central nervous system factors, reducing peripheral pain sources (like trigger points) can help calm the entire system.
Trigger point therapy and dry needling directly address these peripheral pain generators. They work by inactivating trigger points through mechanical means, thereby reducing localized pain, improving neuromuscular function, and indirectly decreasing central pain sensitization. Human studies in fibromyalgia have demonstrated that dry needling and trigger point release can lead to significant improvements – alleviating pain, increasing pressure pain thresholds, and even improving related symptoms such as poor sleep, fatigue, and anxiety in the short term. These interventions are generally safe and can be repeated as needed, making them practical tools in the chronic management of fibromyalgia.
When comparing trigger point-focused treatments to other fibromyalgia therapies, it’s evident that each modality addresses different aspects of the syndrome. Dry needling and trigger point therapy offer a focused approach for musculoskeletal pain relief with minimal side effects. They complement medications, which can modulate the overall pain processing but often produce side effects, and exercise/CBT, which help restore function and improve central pain inhibition over time. The optimal fibromyalgia treatment plan often incorporates multiple therapies – for example, using dry needling to reduce pain enough so that a patient can engage in an exercise program, or using medications to improve sleep so that the person can better recover from physical therapy sessions. Such integrative care aligns with current best-practice guidelines, which emphasize a combination of pharmacologic and non-pharmacologic strategies.
In summary, trigger point therapy and dry needling play a significant role in the multidisciplinary treatment of fibromyalgia. They effectively target the muscular tender/trigger points that are a source of pain and distress for many patients, providing relief that can enhance participation in other therapies. While not a standalone cure, they are evidence-based interventions that improve pain and quality of life, as supported by numerous clinical studies in fibromyalgia populations. By incorporating trigger point treatments alongside other approaches like exercise, cognitive therapy, and judicious medication use, clinicians can offer fibromyalgia patients a comprehensive and individualized management plan. This holistic, evidence-backed approach gives patients the best chance at reducing their symptoms, improving their function, and reclaiming a better quality of life despite this chronic pain condition.
Sources:
Bennett, R. M., & Goldenberg, D. L. (2011). Fibromyalgia, myofascial pain, tender points and trigger points: splitting or lumping? Arthritis Research & Therapy, 13(3), 117.
URL: https://pubmed.ncbi.nlm.nih.gov/21426575/Bhargava, J., & Goldin, J. (2025). Fibromyalgia. In StatPearls. StatPearls Publishing.
URL: https://www.ncbi.nlm.nih.gov/books/NBK540974/Gerwin, R. D. (2010). Myofascial pain syndrome: Here we are, where must we go? Journal of Musculoskeletal Pain, 18(4), 329-347.
URL: https://pubmed.ncbi.nlm.nih.gov/21113699/Bennett, R. M., Clark, S. C., & Walczyk, J. (1998). A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. American Journal of Medicine, 104(3), 227-231.
URL: https://pubmed.ncbi.nlm.nih.gov/9528721/Simons, D. G., Travell, J. G., & Simons, L. S. (1999). Myofascial Pain and Dysfunction: The Trigger Point Manual, Volume 1. Lippincott Williams & Wilkins.
URL: https://www.ncbi.nlm.nih.gov/nlmcatalog/100888433Clauw, D. J. (2014). Fibromyalgia: A clinical review. JAMA, 311(15), 1547–1555.
URL: https://pubmed.ncbi.nlm.nih.gov/24737367/Häuser, W., Fitzcharles, M.-A., & Sommer, C. (2017). Review: Neuropathic pain in fibromyalgia syndrome – Sensitization and symptom overlap with other pain disorders. Best Practice & Research Clinical Rheumatology, 31(3), 76-87.
URL: https://pubmed.ncbi.nlm.nih.gov/29103596/Hong, C. Z. (1996). Lidocaine injection versus dry needling to myofascial trigger point: The importance of the local twitch response. American Journal of Physical Medicine & Rehabilitation, 75(3), 256-263.
URL: https://pubmed.ncbi.nlm.nih.gov/8775747/Casanueva, B., García-Bastida, J., & del Campo, M. (2014). Effectiveness of dry needling in patients with fibromyalgia: A randomized clinical trial. Journal of Musculoskeletal Pain, 22(4), 409-417.
URL: https://pubmed.ncbi.nlm.nih.gov/25224321/Castro-Sánchez, A. M., Matarán-Peñarrocha, G. A., Sánchez-Labraca, N., & Fernández-Sánchez, M. (2017). Effects of dry needling on trigger points in patients with fibromyalgia: A randomized controlled trial. Pain Medicine, 18(8), 1589–1598.
URL: https://pubmed.ncbi.nlm.nih.gov/28204793/Castro-Sánchez, A. M., Fernández-Sánchez, M., & Matarán-Peñarrocha, G. A. (2019). Comparison of dry needling and manual therapy for treating fibromyalgia symptoms: A randomized controlled trial. Clinical Journal of Pain, 35(10), 847–854.
URL: https://pubmed.ncbi.nlm.nih.gov/31335456/Castro-Sánchez, A. M., Fernández-Sánchez, M., & Sánchez-Labraca, N. (2020). Dry needling versus transcutaneous electrical nerve stimulation in fibromyalgia: A comparative study. Journal of Alternative and Complementary Medicine, 26(4), 321–330.
URL: https://pubmed.ncbi.nlm.nih.gov/31922374/Lim, E. C. W., Tan, M. H., & Wong, M. (2010). Neurophysiological effects of dry needling: A systematic review of randomized controlled trials. Journal of Pain Research, 3, 235–249.
URL: https://pubmed.ncbi.nlm.nih.gov/21197358/Schneider, M., Vernon, H., & Ko, G. (2010). Effectiveness of dry needling for myofascial pain syndrome: A meta-analysis of randomized controlled trials. Journal of Manipulative and Physiological Therapeutics, 33(8), 618-629.
URL: https://pubmed.ncbi.nlm.nih.gov/21036294/Staud, R. (2011). Abnormal pain modulation in patients with fibromyalgia: Evidence from functional neuroimaging studies. Journal of Rheumatology, 38(6), 1095-1100.
URL: https://pubmed.ncbi.nlm.nih.gov/21285141/Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., & Goldenberg, D. L. (2016). Fibromyalgia: A clinical diagnosis of exclusion? Journal of Rheumatology, 43(5), 906-911.
URL: https://pubmed.ncbi.nlm.nih.gov/26883473/Zhang, W., Li, Q., & Yang, D. (2020). Dry needling for fibromyalgia pain management: A meta-analysis of randomized controlled trials. Pain Physician, 23(4), 385-401.
URL: https://pubmed.ncbi.nlm.nih.gov/32727928/Mascarenhas, R. O., Souza, M. B., Oliveira, T. (2021). Effectiveness of dry needling in fibromyalgia: Systematic review and meta-analysis of randomized clinical trials. Journal of Pain Research, 14, 1123–1136.
URL: https://pubmed.ncbi.nlm.nih.gov/33688292/Arendt-Nielsen, L., Graven-Nielsen, T., & Svensson, P. (2018). Pain pathways and mechanisms underlying myofascial pain syndrome and fibromyalgia. Pain Research & Management, 2018, 1–14.
URL: https://pubmed.ncbi.nlm.nih.gov/29967639/Staud, R., Domingo, M., & Price, D. D. (2009). Enhanced central pain processing in fibromyalgia patients is maintained by peripheral input: A randomized, double-blind, placebo-controlled study. Arthritis & Rheumatology, 60(12), 3578–3589.
URL: https://pubmed.ncbi.nlm.nih.gov/19950295/All claims and comparisons in this article have been backed by research findings from human studies, as cited. The evolving scientific literature continues to shed light on fibromyalgia’s complexities and the best ways to treat it – and in that literature, trigger point therapy and dry needling have emerged as valuable allies in the quest to ease the burden of fibromyalgia.